Skin Solutions

In 2026, tranexamic acid (TXA) is viewed less as a simple brightening ingredient and more as a regulator of the inflammation–pigment feedback loop. Clinical observations show that barrier damage, micro-inflammation,...

Hyperpigmentation in 2026 is increasingly viewed as an inflammatory memory issue rather than simple pigment accumulation. Clinical observations show that barrier instability, micro-inflammation, and over-treatment often drive rebound darkening and...

In 2026, BAO Laboratory distinguishes dark spots and melasma as biologically different conditions requiring separate formulation strategies. Dark spots mainly involve superficial inflammation and respond well to TXA, niacinamide, and...

In 2026, hyperpigmentation treatment is shifting from high-strength actives to irritation-aware, barrier-friendly formulations. Modern systems use encapsulated tranexamic acid (TXA), niacinamide, and barrier lipids to control inflammation and improve long-term...

This article explains how BAO Laboratory approaches dark spot treatment using Tranexamic Acid (TXA) in 2026 skincare systems focused on irritation control rather than aggressive exfoliation. It describes pigmentation as...

This article explains the role of Tranexamic Acid (TXA) in modern hyperpigmentation care using BAO Laboratory’s formulation approach. It describes how TXA has evolved from a medical anti-bleeding drug into...